News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Imgenex Corporation Now Offers An ELISA Kit To Measure Severe Acute Respiratory Syndrome -SARS- Coronavirus Nucleocapsid Protein


10/19/2005 5:10:54 PM

SAN DIEGO--(BUSINESS WIRE)--April 13, 2004--A leading provider of antibodies against SARS proteins, IMGENEX is proud to offer a sandwich ELISA kit to quantitatively measure the presence of SARS nucleocapsid (SARS-N) protein in infected cells or serum. Thought to be the most prominent protein in culture supernatants infected with SARS virus, the 46-kDa nucleocapsid protein can be detected by anti-nucleocapsid protein antibodies in SARS patients as early as 6 to 10 days post-infection. This suggests the nucleocapsid protein is a major immunogen and may be useful for early diagnosis of SARS infection. A number of PCR-based diagnostic tests are commercially available for detection of the SARS virus; however, very few ELISA kits are available for studying expression of different SARS proteins in experimental systems. At present, this sensitive ELISA kit is available for research use only. "We believe the SARS-N ELISA kit will greatly facilitate research on SARS infection," said Gita Singh, director of Molecular Biology at IMGENEX.

Since its first appearance in November 2002, SARS coronavirus (SARS-CoV), identified as the causative agent of Severe Acute Respiratory Syndrome (SARS), has affected thousands of individuals and become a global concern. Coronaviruses, which are the major cause of upper respiratory tract illness and accounts for as much as 33% of all cases of the common cold, are positive stranded RNA viruses containing one of the largest viral RNA genomes known to date.

About Imgenex

IMGENEX Corp. (www.imgenex.com) with offices at San Diego and Bhubaneswar, India, develops and commercializes novel reagents for the scientific study of human biology and disease and for the production of new diagnostic assays and potential therapies of such diseases. These novel reagents include antibodies, gene and protein expression systems, arrays of various cells and tissues, and siRNA interference systems for use in studies of functional genomics. Areas of biological interest at IMGENEX include cancer, apoptosis (programmed cell death), molecular signaling pathways, cellular aging, and metabolic and infectious diseases.

Contacts

IMGENEX Corp., San Diego Sujay Singh, Ph.D. or Lisa Stein, Ph.D., 858-642-0978 Toll free: 888-723-GENE (4363) Fax: 858-642-0937 ssingh@imgenex.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES